On Mar. 7, 2022, the U.S. Food and Drug Administration announced it had made a low-risk determination for the marketing of products by Minnesota-based Acceligen, including food, from two genome-edited beef cattle and their offspring after determining that the intentional genomic alteration (IGA) does not raise any safety concerns (low-risk determination).

The IGA results in the equivalent genotype (genetic make-up) and short-hair coat trait seen in some conventionally bred cattle, known as a ﾓslickﾔ coat. This was the FDAﾒs first low-risk determination for enforcement discretion for an IGA in an animal for food use.